生长激素缺乏症市场规模、份额和成长分析（按类型、诊断、治疗方法、给药途径、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，生长激素缺乏症市场规模将达到 39 亿美元，到 2025 年将成长至 41.2 亿美元，到 2033 年将成长至 63.2 亿美元，在预测期（2026-2033 年）内复合年增长率为 5.5%。

由于脑损伤、遗传疾病和先天性异常等因素，生长激素缺乏症 (GHD) 的发生率不断上升，推动了对生长激素荷尔蒙疗法的需求。在英国，大约每 3500 至 4000 名儿童中就有 1 名患有儿童GHD，促进了该行业的扩张。这一成长趋势推动了旨在开发创新治疗方法的研发活动。该领域的最新进展展现了行业的强劲势头，新治疗方法获​​得上市核准的显着成功也体现了致力于满足患者需求的决心。随着人们对 GHD 的认识不断提高以及治疗方案的不断改进，荷尔蒙疗法市场预计将显着增长，并被视为投资和创新的关键领域。

生长激素缺乏症市场成长要素

全球生长激素缺乏症市场的主要驱动因素之一是医疗专业人员和大众对生长激素缺乏症 (GHD) 的认识和盛行率不断提高。随着教育活动和研究不断揭示 GHD 的症状和长期影响，越来越多的人开始寻求诊断和治疗方案。医疗技术和诊断工具的进步进一步增强了这种认识，使得 GHD 病例的识别更加精准。此外，荷尔蒙疗法作为一种有效的治疗选择，其日益普及也推动了对荷尔蒙疗法的需求，从而促进了市场成长。

生长激素缺乏症市场限制

全球生长激素缺乏症市场的主要限制因素之一是生长激素荷尔蒙疗法的高成本。治疗相关费用，包括合成荷尔蒙的价格、监测和持续咨询等，对许多患者和医疗系统而言都难以负担。这种经济负担会限制患者获得必要治疗的机会，尤其是在中低收入国家，并阻碍整体市场成长。此外，保险覆盖范围的差异和缺乏统一的治疗指南也构成了进一步的障碍，可能妨碍及时干预，并增加未治疗的生长激素缺乏症病例数。

生长激素缺乏症市场趋势

生长激素缺乏症市场正经历着变革性的转变，这主要得益于药物传递系统的技术进步。穿戴式贴片、无针装置和自动注射器等创新技术正在提升生长激素荷尔蒙疗法的便利性和患者依从性。长效製剂和植入式装置的出现，实现了药物的缓释性释放和给药，从而减少了给药频率，并提高了患者满意度。这种改变不仅改善了治疗效果，也使更多不同背景的患者能够获得治疗。药物输送系统的持续发展，为专注于生长激素缺乏症的製药产业创造了巨大的成长和扩张机会。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

全球生长激素缺乏症市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 儿童生长激素缺乏症
• 成人生长激素缺乏症

全球生长激素缺乏症市场规模（按诊断和复合年增长率划分）（2026-2033 年）

• 血液检查
• 影像检查
• 电脑断层扫描（CT）
• 磁振造影（MRI）
• 其他的

全球生长激素缺乏症市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 药物治疗
• 重组人体生长荷尔蒙
• 人类脑下垂体萃取物
• 外科手术

全球生长激素缺乏症市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 静脉注射
• 肌肉内注射
• 其他的

全球生长激素缺乏症市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 居家医疗
• 专科诊所
• 其他的

全球生长激素缺乏症市场规模（按分销管道和复合年增长率划分）（2026-2033 年）

• 医院药房
• 网路药房
• 零售药房

全球生长激素缺乏症市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Novo Nordisk A/S（Denmark）
• Ipsen SA（France）
• Ascendis Pharma A/S（Denmark）
• Ferring Pharmaceuticals（Switzerland）
• OPKO Health Inc.（USA）
• Genexine, Inc.（South Korea）
• LG Chem Ltd.（South Korea）
• Anhui Anke Biotechnology（China）
• Teva Pharmaceutical Industries Ltd.（Israel）
• JCR Pharmaceuticals Co., Ltd.（Japan）
• Shanghai United Cell Biotechnology Co., Ltd.（China）
• Hanmi Pharmaceutical Co., Ltd.（South Korea）
• Strongbridge Biopharma plc（USA）
• GeneScience Pharmaceuticals Co., Ltd.（China）
• Cipla Limited（India）
• BIOCAD（Russia）
• Krka, dd（Slovenia）
• OPBIO Factory Co., Ltd.（South Korea）

结论与建议

Growth Hormone Deficiency Market size was valued at USD 3.9 Billion in 2024 and is poised to grow from USD 4.12 Billion in 2025 to USD 6.32 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The rising incidence of growth hormone deficiency (GHD), driven by factors such as brain injuries, genetic disorders, and congenital abnormalities, is increasing the demand for growth hormone therapies. In the UK, pediatric GHD affects approximately 1 in every 3,500 to 4,000 children, contributing to the industry's expansion. This growing prevalence is prompting intensified research and development efforts aimed at innovative treatments. Recent advancements in the field underscore the industry's momentum, with notable achievements in securing marketing authorizations for new therapies, reflecting a commitment to addressing the needs of affected populations. As awareness of GHD expands and treatment options evolve, the market for growth hormone therapies is poised for significant growth, highlighting a critical area for investment and innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segments Analysis

Global Growth Hormone Deficiency Market is segmented by Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Diagnosis, the market is segmented intoBlood Tests, Imaging Tests, Computerized tomography (CT) scans, Magnetic resonance imaging (MRI) and Others. Based on Treatment, the market is segmented into Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery. Based on Route of Administration, the market is segmented into Intravenous, Intramuscular and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Growth Hormone Deficiency Market

One key market driver for the global growth hormone deficiency market is the increasing awareness and prevalence of growth hormone deficiency (GHD) among both healthcare professionals and the general public. As educational initiatives and research highlight the symptoms and long-term impacts of GHD, more individuals are seeking diagnosis and treatment options. This rising awareness is compounded by advancements in medical technology and diagnostic tools, leading to better identification of GHD cases. Furthermore, the acceptance of hormone therapy as a viable treatment option has resulted in a growing demand for growth hormone therapies, thereby propelling market growth.

Restraints in the Growth Hormone Deficiency Market

One of the key market restraints for the global growth hormone deficiency market is the high cost associated with growth hormone therapy. The expenses related to treatment, including the price of synthetic hormones, monitoring, and ongoing medical consultations, can be prohibitive for many patients and healthcare systems. This financial burden may limit access to necessary therapies, particularly in low- and middle-income countries, hindering overall market growth. Additionally, insurance coverage discrepancies and the lack of universal guidelines for treatment can create further barriers, preventing timely intervention and leading to unaddressed cases of growth hormone deficiency.

Market Trends of the Growth Hormone Deficiency Market

The Growth Hormone Deficiency market is experiencing a transformative shift driven by technological advancements in drug delivery systems. Innovations such as wearable patches, needle-free devices, and autoinjectors are enhancing the convenience and adherence to growth hormone therapies. The rise of long-acting formulations and implantable devices allows for extended-release and sustained delivery, minimizing the frequency of dosing and improving patient satisfaction. This evolution not only leads to better treatment outcomes but also boosts accessibility for diverse patient populations. As the landscape of drug delivery continues to evolve, it creates significant opportunities for growth and expansion within the pharmaceutical industry focused on Growth Hormone Deficiency.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Growth Hormone Deficiency Market Size by Type & CAGR (2026-2033)

• Market Overview
• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency

Global Growth Hormone Deficiency Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Imaging Tests
• Computerized tomography (CT) scans
• Magnetic resonance imaging (MRI)
• Others

Global Growth Hormone Deficiency Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
• Recombinant Human Growth Hormone
• Human Pituitary Gland Extracts
• Surgery

Global Growth Hormone Deficiency Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Intramuscular
• Others

Global Growth Hormone Deficiency Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Growth Hormone Deficiency Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Growth Hormone Deficiency Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genexine, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai United Cell Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOCAD (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d. (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPBIO Factory Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations